Passive antibody therapy in emerging infectious diseases  

作　　者：Xiaoming Yang 

机构地区：[1]National Engineering Technology Research Center for Combined Vaccines,Wuhan 430207,China [2]Wuhan Institute of Biological Products Co.,Ltd.,Wuhan 430207,China [3]China National Biotec Group Company Limited,Beijing 100029,China

出　　处：《Frontiers of Medicine》2023年第6期1117-1134,共18页医学前沿（英文版）

摘　　要：The epidemic of corona virus disease 2019(COVID-19)caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern(VOCs)has been ongoing for over 3 years.Antibody therapies encompassing convalescent plasma,hyperimmunoglobulin,and neutralizing monoclonal antibodies(mAbs)applied in passive immunotherapy have yielded positive outcomes and played a crucial role in the early COVID-19 treatment.In this review,the development path,action mechanism,clinical research results,challenges,and safety profile associated with the use of COVID-19 convalescent plasma,hyperimmunoglobulin,and mAbs were summarized.In addition,the prospects of applying antibody therapy against VOCs was assessed,offering insights into the coping strategies for facing new infectious disease outbreaks.

关 键 词：SARS-CoV-2 COVID-19 convalescent plasma hyperimmunoglobulin neutralizing monoclonal antibodies 

分 类 号：R373[医药卫生—病原生物学]